Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Synlogic (SYBX)
NASDAQ:SYBX
Holding SYBX?
Track your performance easily
SYBX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.22 - $5.12
Previous Close$1.42
Volume23.75K
Average Volume (3M)8.73K
Market Cap
$16.61M
Enterprise Value-$3.36M
Total Cash (Recent Filing)$19.97M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Mar 13, 2025EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.71
Shares Outstanding11,696,109
10 Day Avg. Volume17,195
30 Day Avg. Volume8,726
Standard Deviation0.21
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.07
Price to Sales (P/S)5.24
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.06
Enterprise Value/Gross Profit-1.00
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Synlogic News
PremiumCompany Announcements
Synlogic Reports Q3 2024 Financial Outcomes
PremiumCompany Announcements
Synlogic Appoints James Flynn to Board Amidst Director ResignationsBulls Say, Bears Say
Bulls Say
Capital ManagementSYBX's prudent capital management is evident from its impressive cash reserves and zero net debt.
Financial PerformanceSYBX boasts a strong financial position with zero net debt to total capital.
LiquiditySYBX maintains a solid liquidity profile with $20M in cash, cash equivalents, and short-term marketable securities.
Bears Say
Program DiscontinuationSYBX announced a surprising decision to discontinue their lead program, SYNB1934 in phenylketonuria (PKU).
Strategic EvaluationThere are low expectations that SYBX's programs will be acquired for further development.
Study ResultsThe company saw no trends in Phe lowering from their open-label portion of the study.
---
Ownership Overview
17.92% Insiders
3.32% Mutual Funds
<0.01% Other Institutional Investors
77.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SYBX FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was $1.22 and its highest was $5.12 in the past 12 months.
What is Synlogic’s market cap?
Currently, no data Available
When is Synlogic’s upcoming earnings report date?
Synlogic’s upcoming earnings report date is Mar 13, 2025 which is in 112 days.
How were Synlogic’s earnings last quarter?
Synlogic released its earnings results on Nov 07, 2024. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.17.
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate is -$0.1.
How many shares outstanding does Synlogic have?
Synlogic has 11,696,109 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Synlogic reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -2.797%.
Which hedge fund is a major shareholder of Synlogic?
Among the largest hedge funds holding Synlogic’s share is RA Capital Management. It holds Synlogic’s shares valued at N/A.
---
Synlogic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
SYBX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 307.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $110.6 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.24%
12-Months-Change
Fundamentals
Return on Equity
-158.75%
Trailing 12-Months
Asset Growth
-72.71%
Trailing 12-Months
Company Description
Synlogic
Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.
---
SYBX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering SYBX
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-53.40%
initiated a buy rating 12 months ago
Copying James Molloy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -53.40% per trade.
---